UNSPSC 51144303: Phendimetrazine tartrate

This classification denotes a cns stimulant and anorexiant with the molecular formula C12H17NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6985IP0T80, chemically known as morpholine, 3,4-dimethyl-2-phenyl-, tartrate, d- but more generally known as phendimetrazine tartrate, which bears US NIH Compound Identifier 120608. European Medicines Agency schedules Phendimetrazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03739MIG.

UNSPSC 51144303 Phendimetrazine tartrate is a Commodity code that in recent state and local procurement activity encompasses a broader spectrum of pharmaceutical procurement than the code name alone suggests—state and local buyers are soliciting everything from naloxone and drug deactivation systems for community health initiatives to generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), reflecting a mix of direct county procurement, state agency procurement, and cooperative vehicles serving multiple participating jurisdictions. The work involves both operational procurement of finished pharmaceutical products for immediate public-health deployment and strategic sourcing of generic and OTC products for statewide or multistate distribution networks.

Recent activity shows strong concentration in the South and Upper Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023, per the posting) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring electronic bidding through the county's e-Procurement Portal and including FEMA compliance requirements. The Texas HHS Commission issued a Request for Information (RFI) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. MMCAP, administering Minnesota Department of Administration procurement on behalf of participating state and local government facilities including Oregon, released an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with awarded vendors to commence July 1, 2026 and contract terms of two years with optional extensions. Vendors pursuing this code should expect detailed product and manufacturing documentation, cGMP and Drug Supply Chain Security Act compliance certification, and participation in established wholesale distribution networks or direct-to-manufacturer channels.